Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
TANDEM DIABETES CARE INC incurred convertible notes of $300.0 million aggregate principal amount with U.S. Bank Trust Company, National Association at 0.00% maturing March 15, 2032.
- Instrument
- convertible notes
- Principal
- $300.0 million aggregate principal amount
- Counterparty
- U.S. Bank Trust Company, National Association
- Rate
- 0.00%
- Maturity
- March 15, 2032
- Event
- incurrence
Exact text from the filing
On February 27, 2026, Tandem Diabetes Care, Inc. (the “Company”) completed its previously announced private offering (the “Offering”) of $300.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2032 (the “Notes”), including the exercise in full of the initial purchasers’ option to purchase up to an additional $35.0 million principal amount of Notes.
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
TANDEM DIABETES CARE INC issued convertible note to initial purchasers for $300.0 million aggregate principal amount.
- Security
- convertible note
- Purchaser
- initial purchasers
- Consideration
- $300.0 million aggregate principal amount
Exact text from the filing
Material Agreement. Indenture and Notes On February 27, 2026, Tandem Diabetes Care, Inc. (the “Company”) completed its previously announced private offering (the “Offering”) of $300.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2032 (the “Notes”), including the exercise in full of the initial purchasers’ option to purchase up to an
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
TANDEM DIABETES CARE INC entered into Indenture with U.S. Bank Trust Company, National Association valued at $300.0 million aggregate principal amount (effective 2026-02-27).
- Action
- entry
- Agreement
- notes offering
- Counterparty
- U.S. Bank Trust Company, National Association
- Value
- $300.0 million aggregate principal amount
- Effective
- 2026-02-27
Exact text from the filing
On February 27, 2026, Tandem Diabetes Care, Inc. (the “Company”) completed its previously announced private offering (the “Offering”) of $300.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2032 (the “Notes”), including the exercise in full of the initial purchasers’ option to purchase up to an additional $35.0 million principal amount of Notes. The Notes were issued in accordance with an indenture, dated February 27, 2026 (the “Indenture”), between the Company and U.S. Bank Trust Company, National Association, as trustee.
View on SEC.gov